MARKET INSIGHTS

Global Neuropilin 1 (NRP1) ELISA Kit market was valued at USD 10.7 million in 2024. The market is projected to grow from USD 11.5 million in 2025 to USD 17.5 million by 2031, exhibiting a CAGR of 7.5% during the forecast period.

Neuropilin 1 (NRP1) ELISA Kits are immunoassay tools designed to quantify NRP1 protein concentrations in biological samples. NRP1 is a transmembrane receptor protein that plays critical roles in angiogenesis, axon guidance, and immune regulation. These kits utilize antibody-based detection methods to provide researchers with precise measurements of NRP1 expression levels, which are increasingly important for studying cancer progression, neurological disorders, and cardiovascular diseases.

The market growth is driven by rising demand for reliable protein quantification tools in academic and clinical research, particularly in oncology and neuroscience applications. However, the high cost of specialized ELISA kits and stringent regulatory requirements present challenges for market expansion. Key manufacturers are focusing on product innovations, with recent developments including improved sensitivity formats and multiplexing capabilities to meet evolving research needs.

MARKET DYNAMICS

MARKET DRIVERS

Growing Research in Neurobiology and Angiogenesis to Accelerate Market Growth

The Neuropilin 1 (NRP1) ELISA Kit market is witnessing robust growth due to increasing research activities in neurobiology and angiogenesis. NRP1 plays a critical role in neural development and vascular formation, making it a key protein of interest in studying neurodegenerative diseases and cancer. With over 55 million people worldwide affected by Alzheimer's and other dementias, the demand for precise protein quantification tools like ELISA kits has surged. Recent studies have also highlighted NRP1's involvement in tumor angiogenesis, driving adoption in oncology research. The global cancer burden, expected to reach 28.4 million cases by 2040, further underscores the need for reliable NRP1 detection methods in drug development and diagnostic applications.

Technological Advancements in Protein Detection Methods Fueling Adoption

Continuous improvements in ELISA technology are significantly enhancing the accuracy and sensitivity of NRP1 detection. Modern ELISA kits now offer detection limits as low as 0.1 ng/mL with reduced cross-reactivity, making them indispensable for clinical research. The integration of automated platforms has increased throughput capabilities by 40-60% compared to traditional methods, particularly benefiting large-scale studies and diagnostic laboratories. These advancements have led to wider adoption in pharmaceutical quality control and academic research settings, where precise protein quantification is paramount for validating experimental results and drug efficacy.

For instance, recent enhancements in multiplex ELISA technology now allow simultaneous detection of NRP1 with other angiogenesis markers, providing comprehensive profiling in single assays.

Furthermore, the growing emphasis on biomarker discovery in precision medicine has created additional demand for high-performance ELISA kits. Pharmaceutical companies are increasingly incorporating NRP1 analysis in their drug development pipelines, particularly for anti-angiogenesis therapies targeting solid tumors.

MARKET CHALLENGES

High Development Costs and Technical Complexities in Assay Optimization

While the NRP1 ELISA Kit market shows promising growth, manufacturers face significant challenges in assay development and optimization. Producing antibodies with high specificity for NRP1's various isoforms requires extensive R&D investments, with development cycles often exceeding 18 months. The complexity increases further when accommodating different sample types (serum, plasma, cell lysates), each requiring unique matrix interference solutions. These technical hurdles contribute to the premium pricing of specialized ELISA kits, potentially limiting accessibility for smaller research institutions.

Other Challenges

Sample Stability Issues
NRP1's susceptibility to degradation in biological samples creates pre-analytical challenges that affect assay reproducibility. Proper sample handling protocols add operational complexity and cost to research workflows, particularly in multi-center clinical studies.

Cross-reactivity Concerns
The structural similarity between NRP1 and related proteins like NRP2 demands rigorous antibody validation to ensure assay specificity. False-positive results can compromise research outcomes, requiring additional confirmatory tests that extend project timelines and budgets.

MARKET RESTRAINTS

Competition from Alternative Technologies Limiting Market Penetration

The NRP1 ELISA Kit market faces growing competition from emerging protein detection methods. Mass spectrometry-based proteomics, though more expensive, provides comprehensive protein profiling that appeals to researchers needing multi-analyte data. Flow cytometry adoption has increased by approximately 25% in immunology research, as it enables single-cell NRP1 expression analysis with spatial resolution. While ELISA maintains advantages in quantitative accuracy and cost-effectiveness for focused studies, these alternative technologies are capturing market share in applications requiring higher dimensionality data.

Additionally, the development of CRISPR-based detection systems and microfluidic platforms presents long-term competitive threats. These technologies promise faster turnaround times and reduced sample volumes, though they currently lack the established validation track record of ELISA methods.

MARKET OPPORTUNITIES

Expanding Applications in COVID-19 and Autoimmune Disease Research Creating New Growth Avenues

Emerging research has identified NRP1 as a potential mediator in COVID-19 pathogenesis and autoimmune disorders, opening new market opportunities. Recent studies suggest NRP1 facilitates SARS-CoV-2 viral entry in olfactory neurons, sparking interest in its role in neurological complications. The autoimmune disease diagnostic sector, projected to grow at 8.3% CAGR, increasingly incorporates NRP1 analysis for conditions like multiple sclerosis. These expanding applications are driving demand for specialized ELISA kits optimized for novel sample types and disease-specific isoforms.

Strategic partnerships between kit manufacturers and academic medical centers are accelerating the development of application-specific assays. Such collaborations leverage clinical expertise to enhance kit performance for emerging research needs while expanding market reach through institutional networks.

Neuropilin 1 (NRP1) ELISA Kit Market

The global Neuropilin 1 (NRP1) ELISA Kit market was valued at US$ 10.7 million in 2024 and is projected to reach US$ 17.5 million by 2031, exhibiting a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2024 to 2031. Neuropilin 1 (NRP1) ELISA Kits serve as essential experimental tools for quantifying the concentration of the Neuropilin 1 protein in biological samples. NRP1, a transmembrane glycoprotein, plays critical roles in various physiological processes, including neural development, axon guidance, angiogenesis, cell migration, and immune modulation. These kits utilize enzyme-linked immunosorbent assay (ELISA) technology, where specific antibodies capture NRP1, and a colorimetric reaction enables precise measurement of protein levels through absorbance changes. This methodology supports in-depth investigations into NRP1's functions in neurobiology, signal transduction pathways, and disease pathologies, such as cancer and vascular disorders, thereby facilitating advancements in biomedical research and clinical diagnostics.

The demand for NRP1 ELISA Kits is driven by increasing research into co-receptor signaling involving vascular endothelial growth factor (VEGF) and semaphorins, which are implicated in tumor progression and therapeutic targeting. Manufacturers and suppliers emphasize product innovation, including kits optimized for high sensitivity and specificity across diverse sample types like serum, plasma, and cell lysates. Industry trends highlight a shift toward multiplex assays and automation-compatible formats to enhance throughput in laboratories. Key challenges include supply chain disruptions for antibodies and enzymes, alongside regulatory hurdles for clinical-grade reagents. Potential risks encompass competition from alternative protein detection methods like Western blotting or mass spectrometry, though ELISA's simplicity and cost-effectiveness maintain its prominence.

This report provides a comprehensive overview of the global NRP1 ELISA Kit market, incorporating quantitative forecasts for revenue and qualitative insights into competitive dynamics, growth strategies, and market positioning. It analyzes sales volumes, pricing trends, and recent developments among leading participants to aid stakeholders in informed decision-making.

Segment Analysis:

By Type

Human NRP1 ELISA Kit Segment Dominates the Market Due to its Extensive Application in Clinical and Oncological Research

The market is segmented based on type into:

• Human

• Mouse

• Rat

• Porcine

• Others

By Application

Research Institute Segment Leads Due to High Adoption in Biomedical and Neuroscientific Studies

The market is segmented based on application into:

• Hospital

• Research Institute

• Others

Key Players

The competitive landscape features several prominent manufacturers and suppliers specializing in immunoassay kits. Leading companies include:

• Elabscience Biotechnology Inc.

• LifeSpan BioSciences, Inc.

• Abcam

• Wuhan Fine Biotech Co., Ltd.

• Bio-Techne

• MyBiosource, Inc.

• RayBiotech, Inc.

• ZellBio GmbH

• Boster Biological Technology

• Biomatik

• Assay Genie

• CLOUD-CLONE CORP.

• ZodelBiotec Ltd.

• Innovative Research

• OriGene Technologies, Inc.

• Geno Technology, Inc.

These players collectively drive market innovation through product launches tailored for NRP1 detection, focusing on improved assay performance and broader species compatibility to meet evolving research needs.

COMPETITIVE LANDSCAPE

Key Industry Players

Companies Strive to Strengthen their Product Portfolio to Sustain Competition

The competitive landscape of the Neuropilin 1 (NRP1) ELISA Kit market is semi-consolidated, featuring a mix of large, medium, and small-sized players that collectively drive innovation and accessibility in this niche segment of biotechnology tools. This market, valued at approximately US$10.7 million in 2024 and projected to reach US$17.5 million by 2031 with a compound annual growth rate (CAGR) of 7.5%, sees intense rivalry centered on product accuracy, ease of use, and applications in neurobiology and disease research. Elabscience Biotechnology Inc. stands out as a leading player, bolstered by its comprehensive ELISA kit offerings tailored for detecting NRP1 protein levels in various biological samples, along with a robust global distribution network spanning North America, Europe, and Asia.

Abcam and Bio-Techne also commanded significant market shares in 2024, thanks to their innovative portfolios that emphasize high-sensitivity assays for human, mouse, and other species-specific NRP1 detection. The growth trajectory of these companies stems from their focus on research-driven end-markets, including academic institutions and pharmaceutical labs studying angiogenesis, immune responses, and neural development. For instance, Abcam's commitment to antibody-based technologies has enabled precise quantification of NRP1, a transmembrane co-receptor crucial for VEGF signaling, thereby supporting advancements in cancer and vascular biology research.

Furthermore, ongoing growth initiatives such as geographical expansions into emerging markets like China and India, coupled with frequent new product launches, position these firms to capture a larger slice of the market over the forecast period. While demand for NRP1 ELISA kits rises due to their role in clinical diagnostics and biomedical studies, companies are adapting by enhancing kit compatibility with automated platforms, which reduces assay times and improves reproducibility.

Meanwhile, players like LifeSpan BioSciences, Inc. and MyBiosource, Inc. are bolstering their positions through substantial R&D investments, strategic collaborations with research institutes, and expansions into porcine and other specialized ELISA variants. These efforts not only address challenges like supply chain disruptions but also mitigate risks associated with regulatory compliance in diagnostic applications. However, the market faces obstacles from price fluctuations in raw materials and intense competition from generic suppliers, prompting firms to differentiate via superior validation data and customer support. Overall, this dynamic environment fosters continued innovation, ensuring that key participants maintain competitiveness while contributing to the broader understanding of NRP1's role in health and disease.

List of Key Neuropilin 1 (NRP1) ELISA Kit Companies Profiled

• Elabscience Biotechnology Inc. (China)

• LifeSpan BioSciences, Inc. (U.S.)

• Abcam (U.K.)

• Wuhan Fine Biotech Co., Ltd. (China)

• Bio-Techne (U.S.)

• MyBiosource, Inc. (U.S.)

• RayBiotech, Inc. (U.S.)

• ZellBio GmbH (Germany)

• Boster Biological Technology (U.S.)

• Biomatik (Canada)

• Assay Genie (Ireland)

• CLOUD-CLONE CORP. (U.S.)

• ZodelBiotec Ltd. (U.K.)

• Innovative Research (U.S.)

• OriGene Technologies, Inc. (U.S.)

• Geno Technology, Inc. (U.S.)

NEUROPILIN 1 (NRP1) ELISA KIT MARKET TRENDS

Rising Focus on Angiogenesis and Cancer Research to Drive Market Growth

The global Neuropilin 1 (NRP1) ELISA Kit market has witnessed steady expansion, valued at 10.7 million USD in 2024 and projected to reach 17.5 million USD by 2031, reflecting a compound annual growth rate (CAGR) of 7.5%. This growth is largely propelled by the increasing emphasis on angiogenesis and cancer research, where NRP1 plays a critical role as a co-receptor for vascular endothelial growth factor (VEGF), influencing tumor progression and vascularization. Researchers are leveraging these ELISA kits to quantify NRP1 levels in biological samples, enabling precise insights into disease mechanisms. While traditional assays faced limitations in sensitivity, recent advancements in immunoassay technologies have enhanced detection accuracy, making NRP1 quantification more reliable for preclinical studies.

Furthermore, the integration of NRP1 ELISA kits in immunotherapy development has emerged as a significant trend. As immune checkpoint inhibitors gain traction, understanding NRP1's involvement in immune cell modulation becomes essential. For instance, studies have highlighted NRP1's expression on regulatory T cells, which suppresses anti-tumor responses, prompting the need for targeted quantification tools. This has led to heightened adoption in pharmaceutical R&D pipelines, where kits facilitate high-throughput screening of potential therapeutics. However, challenges such as sample variability and cross-reactivity in multi-analyte assays persist, yet ongoing refinements in antibody specificity are addressing these issues effectively.

Other Trends

Personalized Medicine Initiatives

The surge in personalized medicine is another key driver, amplifying the demand for NRP1 ELISA kits in tailoring treatments for neurological disorders and vascular diseases. NRP1's multifaceted roles in neural development and cell migration make it a biomarker of interest for conditions like Alzheimer's and stroke recovery. By measuring NRP1 concentrations, clinicians can better stratify patients for targeted therapies, fostering a shift toward precision diagnostics. Techniques such as combining ELISA with next-generation sequencing are accelerating this trend, allowing for comprehensive profiling that informs individualized care plans and improves outcomes in chronic disease management.

Expansion in Preclinical Animal Models

Meanwhile, the proliferation of preclinical research using animal models is bolstering kit utilization across species-specific variants like mouse, rat, and porcine. With over 60% of global biomedical studies relying on these models, NRP1 ELISA kits provide vital data on protein expression in disease mimicry, supporting drug efficacy evaluations. This trend is particularly evident in neurotoxicity assessments, where accurate NRP1 detection aids in understanding environmental impacts on neural pathways.

Advancements in Biomedical Diagnostics and Research Infrastructure

The broadening of biomedical diagnostics and research infrastructure is fueling the adoption of NRP1 ELISA kits worldwide, especially in academic and clinical settings. Increased R&D investments, particularly in regions like North America and Asia-Pacific, are leading to innovative applications in studying NRP1's regulatory mechanisms in immune responses and angiogenesis. New product launches from key manufacturers, including enhanced sensitivity kits for low-abundance samples, are meeting diverse needs in hospitals and research institutes. Collaborative initiatives, such as those exploring NRP1 as a therapeutic target in oncology, further underscore the kits' importance in bridging basic science and translational medicine, ultimately driving market accessibility and innovation.

Regional Analysis: Neuropilin 1 (NRP1) ELISA Kit Market

North America
North America holds a significant position in the global Neuropilin 1 (NRP1) ELISA Kit market, driven by its robust biomedical research ecosystem and advanced healthcare infrastructure. The United States, in particular, dominates the regional landscape, supported by substantial funding from the National Institutes of Health (NIH) and private sector investments in biotechnology. NRP1 ELISA kits are widely used in research focused on neural development, angiogenesis, and immune responses, areas where North America leads due to its concentration of top-tier universities, pharmaceutical companies, and contract research organizations. For instance, ongoing studies into NRP1's role in cancer progression and neurobiology heavily rely on these precise quantification tools for protein concentration measurements in biological samples. The market benefits from stringent regulatory standards set by the FDA, which ensure high-quality assay kits that meet rigorous validation criteria for both research and potential clinical applications. Hospitals and research institutes, the primary end-users, are increasingly adopting these kits to support diagnostic advancements in diseases linked to NRP1 dysregulation, such as certain neurological disorders and vascular conditions. While the human-specific ELISA kits remain the most demanded segment, reflecting the region's emphasis on translational medicine, there is also growing interest in mouse and rat variants for preclinical trials. However, challenges like high costs of imported kits and supply chain disruptions can occasionally impact accessibility for smaller labs. Overall, the region's market is projected to grow in alignment with the global trend, fueled by innovation in multiplex assays and automation that enhances the efficiency of NRP1 detection. As collaborations between academia and industry deepen, North America continues to set benchmarks for accuracy and reproducibility in ELISA technologies. Furthermore, the focus on personalized medicine initiatives encourages the integration of NRP1 assays into broader proteomic profiling, promising sustained demand. Economic stability and a favorable environment for biotech startups further bolster market expansion, ensuring that suppliers like those specializing in monoclonal antibody-based kits can thrive. In essence, North America's leadership stems from its integrated approach to research, where NRP1 ELISA kits serve as indispensable tools in unraveling complex biological mechanisms.

Europe
Europe represents a mature and innovation-driven segment of the Neuropilin 1 (NRP1) ELISA Kit market, characterized by strong regulatory frameworks and collaborative research networks. Countries like Germany, France, and the United Kingdom are at the forefront, benefiting from EU-funded programs such as Horizon Europe, which allocate billions to health and life sciences research. These initiatives prioritize investigations into NRP1's multifaceted roles in cell migration, angiogenesis, and immune modulation, making ELISA kits essential for quantifying protein levels in diverse sample types. The region's emphasis on ethical standards and data reproducibility aligns well with the precise, antibody-capture methodologies of NRP1 assays, which measure color changes to determine concentrations accurately. Research institutes and hospitals dominate applications, with a particular surge in demand for human and mouse kits used in studies of neurodegenerative diseases and tumor microenvironments. Compliance with REACH and other environmental regulations influences kit manufacturing, promoting sustainable production practices among suppliers. Despite the post-Brexit landscape, the UK maintains its prowess through institutions like the Wellcome Trust, fostering advancements in NRP1-related diagnostics. Challenges include varying reimbursement policies across member states, which can slow adoption in clinical settings, and the need for harmonized protocols to facilitate cross-border collaborations. However, the push toward precision oncology and neuropharmacology is accelerating market penetration, as ELISA kits provide reliable tools for biomarker discovery. Innovation in kit formats, such as those incorporating fluorescence for higher sensitivity, is gaining traction, supported by Europe's dense cluster of biotech hubs in biotech valleys like Cambridge and Basel. As the continent addresses aging populations and rising chronic disease burdens, NRP1 ELISA kits are poised to play a pivotal role in early detection and therapeutic monitoring. The competitive supplier environment, featuring both local and international players, ensures a diverse range of options tailored to specific research needs. Ultimately, Europe's market dynamics reflect a balanced interplay of regulation, funding, and scientific curiosity, sustaining steady growth amid global expansions.

Asia-Pacific
The Asia-Pacific region is experiencing the most dynamic growth in the Neuropilin 1 (NRP1) ELISA Kit market, propelled by rapid advancements in biotechnology and increasing research investments in countries like China, Japan, and India. This area accounts for a substantial portion of global demand, driven by expansive academic and industrial efforts to explore NRP1's functions in neural development, angiogenesis, and immune responses. In China, government-backed initiatives such as the 14th Five-Year Plan emphasize life sciences, leading to heightened use of ELISA kits in large-scale proteomic studies at premier institutions. Japan, with its focus on regenerative medicine, favors high-sensitivity kits for precise NRP1 quantification in stem cell research, while India's burgeoning pharma sector adopts these tools for cost-effective disease mechanism investigations. The prevalence of research institutes as key applications underscores the region's academic orientation, though hospitals are increasingly incorporating NRP1 assays for clinical trials in oncology and neurology. Type-wise, rat and mouse kits are popular due to extensive animal model usage in preclinical research, complementing the global shift toward translational applications. Cost sensitivity remains a factor, prompting local manufacturing by suppliers to offer competitive pricing without compromising quality. Urbanization and healthcare modernization further catalyze demand, as rising awareness of NRP1's implications in conditions like glioblastoma and vascular anomalies prompts more biomarker studies. However, infrastructural gaps in rural areas and intellectual property concerns pose hurdles to seamless market expansion. Technological integrations, such as automated ELISA platforms, are emerging to address high-throughput needs in busy labs. The region's diverse regulatory landscape, from Japan's PMDA standards to China's NMPA guidelines, ensures kit reliability but requires suppliers to navigate approvals diligently. As collaborations with Western firms grow, Asia-Pacific's market is evolving from volume-driven to innovation-led, with potential for domestic players to capture larger shares. This trajectory aligns with broader economic development, positioning the region as a future powerhouse in NRP1 research tools.

South America
South America is an emerging market for Neuropilin 1 (NRP1) ELISA Kits, with gradual adoption influenced by expanding biomedical research capabilities and healthcare improvements in nations like Brazil and Argentina. The region's focus on tropical diseases and oncology drives interest in NRP1 studies, particularly its roles in angiogenesis and immune regulation, where ELISA kits enable accurate protein quantification for sample analysis. Research institutes lead the demand, supported by partnerships with international funders, though hospitals are slowly integrating these tools for diagnostic purposes amid resource constraints. Human-specific kits are most common, reflecting efforts to address local health challenges like cancer prevalence, while animal models gain traction in veterinary and preclinical work. Brazil's robust university system, including institutions in So Paulo, fosters NRP1-related neurobiology research, but economic fluctuations often limit procurement budgets, favoring affordable imports over premium options. Regulatory progress, such as ANVISA's oversight in Brazil, is enhancing kit quality assurance, yet harmonization across countries remains inconsistent. Challenges like import duties and supply chain logistics hinder faster growth, particularly in remote areas. Nonetheless, rising foreign investments in biotech parks are building capacity, with initiatives promoting local production to reduce dependency. The shift toward collaborative trials in immunology and neurology promises increased utilization of NRP1 assays for mechanism elucidation. As education levels rise and public health funding stabilizes, South America's market shows resilience, offering opportunities for suppliers to tailor offerings to regional needs. While not yet at par with more developed regions, the potential for expansion lies in leveraging NRP1's relevance to endemic conditions, gradually elevating the market's profile.

Middle East & Africa
The Middle East and Africa constitute a nascent yet promising segment of the Neuropilin 1 (NRP1) ELISA Kit market, marked by sporadic infrastructure development and targeted research investments in select countries. In the Middle East, nations like Israel and the UAE are advancing quickly, with Israel's biotech ecosystem emphasizing NRP1's applications in angiogenesis and cancer research through innovative ELISA technologies. The UAE's Vision 2031 initiatives fund health sciences, boosting demand in hospitals and research centers for protein quantification tools that support clinical diagnostics. Africa's market, led by South Africa and emerging hubs in Nigeria, focuses on infectious diseases and neurology, where NRP1 kits aid in studying immune responses and neural pathways. Research institutes dominate usage, often relying on grants from global bodies to acquire these assays. Type preferences lean toward human kits for direct applicability, though others like porcine are niche in veterinary contexts. Regulatory environments vary widely, with stronger frameworks in Israel contrasting weaker enforcement elsewhere, which can delay kit introductions. Funding shortages and geopolitical issues slow progress, but growing medical tourism and urban development in the Gulf states are spurring adoption. Suppliers face opportunities in providing training for local labs to maximize kit efficacy in color-change based measurements. As awareness of NRP1's role in disease mechanisms spreads, the region could see accelerated growth through international partnerships. Long-term, investments in education and facilities will unlock fuller potential, transforming current limitations into avenues for market maturation.

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• Segmentation Analysis

  • By product type or category

  • By application or usage area

  • By end-user industry

  • By distribution channel (if applicable)

• Regional Insights

  • North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

  • Country-level data for key markets

• Competitive Landscape

  • Company profiles and market share analysis

  • Key strategies: M&, partnerships, expansions

  • Product portfolio and pricing strategies

• Technology & Innovation

  • Emerging technologies and R&D trends

  • Automation, digitalization, sustainability initiatives

  • Impact of AI, IoT, or other disruptors (where applicable)

• Market Dynamics

  • Key drivers supporting market growth

  • Restraints and potential risk factors

  • Supply chain trends and challenges

• Opportunities & Recommendations

  • High-growth segments

  • Investment hotspots

  • Strategic suggestions for stakeholders

• Stakeholder Insights

  This report is designed to support strategic decision-making for a wide range of stakeholders, including:

  • Pharmaceutical and biotech companies

  • Medical device and diagnostics manufacturers

  • Healthcare providers and hospital systems

  • Contract research and manufacturing organizations

  • Investors, consultants, and policy makers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global Neuropilin 1 (NRP1) ELISA Kit Market?

-> Global Neuropilin 1 (NRP1) ELISA Kit market was valued at USD 10.7 million in 2024 and is expected to reach USD 17.5 million by 2031.

Which key companies operate in Global Neuropilin 1 (NR1) ELISA Kit Market?

-> Key players include Elabscience Biotechnology Inc., LifeSpan BioSciences, Inc, Abcam, Wuhan Fine Biotech Co., Ltd., and Bio-Techne, among others.

What is the CAGR for the forecast period?

-> The market is projected to grow at a CAGR of 7.5% during the forecast period 20252031.

What are the primary applications?

-> Primary applications include hospital diagnostics, research institutions, and other biomedical research settings.

What are the key product segments?

-> Key product segments include human, mouse, rat, porcine, and other species-specific ELISA kits.